Transaction #14429 · Form 4 · 0001213900-25-117306
Inmune Bio, Inc. · Stock award · Option (right to buy)
Inmune Bio, Inc. · Transacted December 1, 2025 · Filed December 2, 2025
What does this filing report?
An SEC Form 4 filing for Inmune Bio, Inc. records a stock award involving Option (right to buy) on December 1, 2025. The reported quantity was 300,000. The filing date is December 2, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Inmune Bio, Inc.
- Company CIK
- 0001711754
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 300,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 300,000
- Ownership description
- Not reported
- SEC acceptance time
- Dec 2, 2025, 4:42 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Ellspermann Cory Randall ↗
CFO
CIK 0002082083
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 300,000
- Conversion / exercise price
- 1.48
- Exercise date
- Not reported
- Expiration date
- November 23, 2035
Filing footnotes & remarks
- F1
- Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. One-fourth (1/4) of the option will vest 12 months from the date of grant and thereafter the remaining unvested option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested which shall occur on the four-year anniversary of the date of grant.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.